Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
U.S. drug costs lead to lapsed treatment adherence, less viral suppression, more ER, hospital visits for people with HIV, study finds
From 2016 to 2017, 14% of people living with HIV in the United States did something to save money on the out-of-pocket costs of their prescription […]
Combatting MDR TB: Year three – Released four years ago, the federal National Action Plan for Combating Multidrug-Resistant Tuberculosis raised hopes that targets and strategies would […]
This year marks the close of a dynamic decade in global infectious disease research and responses that changed expectations of what humanity can accomplish toward making […]
Wuhan City in the Hubei Province of the People’s Republic of China is on the Yangtze River and is the most populous city in central China. […]